Eli Lilly Agrees to Acquire Merida Biosciences for Up to $2.875 Billion
Eli Lilly (LLY) has announced a deal to acquire Merida Biosciences, a biotechnology company focused on developing therapies targeting the immune system's role in disease treatment and prevention. The acquisition is valued at up to $2.875 billion in cash, including an upfront payment and additional contingent milestone payments tied to future performance or development goals. The transaction is expected to close by Q4 2026, pending customary conditions and regulatory approvals. Merida's pipeline includes several preclinical programs with potential applications across multiple therapeutic areas, which Lilly aims to integrate into its broader portfolio of innovative treatments.
Tickers: $LLY
Topics: acquisitions pharmaceuticals